The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are: 1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI? 2. What are the experiences of patients after AKI? 3. What interventions should be recommended to improve assessment and support of patients after AKI? Participants will be asked to do one or more of: * blood tests to measure kidney function in different ways * have measurement of their body composition * complete questionnaires about their symptoms * have an interview with a researcher about their experiences * discussion to develop an action plan based on findings
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The proportion of eligible patients who agree to participate
Timeframe: 3 months
The proportion of participants who have all three measurements (eGFR-cystatin, eGFR-creatinine and measured GFR)
Timeframe: 3 months
Standard deviation of the difference between measured GFR and eGFR-creatinine and eGFR-cystatin
Timeframe: 3 months
The proportion of patients with eGFR <60ml/min/1.73m2 from eGFR-cystatin compared with eGFR creatinine
Timeframe: 3 months
Gut microbiome composition
Timeframe: 3 months
Codes and themes related to patient experience after AKI, identified from systematic qualitative analysis of interview transcripts
Timeframe: 3 - 12 months
Production of a document of recommended next steps through MDT development during participatory workshops
Timeframe: At completion of third workshop 3 years after enrolment